10x Genomics, Inc. (TXG) Financial Statements (2026 and earlier)

Company Profile

Business Address 6230 STONERIDGE MALL ROAD
PLEASANTON, CA 94588
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments393,402388,695429,984587,447663,603424,166
Cash and cash equivalent344,067359,284219,746587,447663,603424,166
Short-term investments49,33529,411210,238   
Restricted cash and investments   2,6331,02816,567 
Receivables87,862114,832104,21185,25451,20833,371
Inventory, net of allowances, customer advances and progress billings83,10773,70681,62959,96629,95915,270
Inventory83,10773,70681,62959,96629,95915,270
Other undisclosed current assets20,01618,78916,57813,89613,0298,033
Total current assets:584,387596,022635,035747,591774,366480,840
Noncurrent Assets
Operating lease, right-of-use asset57,29065,36169,88260,91846,983 
Property, plant and equipment252,648279,571289,328169,49272,84048,821
Intangible assets, net (including goodwill)20,18221,12727,36929,908  
Goodwill4,5114,5114,5114,511  
Intangible assets, net (excluding goodwill)15,67116,61622,85825,397  
Restricted cash and investments  4,9747,5988,47452,327
Other noncurrent assets4,1293,0622,3923,31926,67823,935
Total noncurrent assets:334,249369,121393,945271,235154,975125,083
TOTAL ASSETS:918,636965,1431,028,9801,018,826929,341605,923
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities72,43271,04071,26367,60135,43730,174
Taxes payable4,6228,6491,087
Employee-related liabilities31,62615,38312,394
Accounts payable12,90915,73821,59917,3514,70913,028
Accrued liabilities59,52355,30249,66414,0026,6963,665
Deferred revenue20,65813,1507,8675,3404,4723,297
Debt      9,882
Deferred compensation liability     247494
Estimated litigation liability    44,173 
Other liabilities8,5134,4136,7075,2755,8443,949
Other undisclosed current liabilities16,03038,55945,12032,14127,95315,253
Total current liabilities:117,633127,162130,957110,357118,12663,049
Noncurrent Liabilities
Long-term debt and lease obligation    76,84757,04219,837
Long-term debt, excluding current maturities      19,837
Liabilities, other than long-term debt90,86996,93892,2808,2403,93018,045
Deferred revenue12,5138,814   834
Deferred rent credit      16,120
Estimated litigation liability      
Other liabilities5,0294,2756,1418,2403,9301,091
Operating lease, liability73,32783,84986,13976,84757,042 
Other undisclosed noncurrent liabilities    5,81411,17184,909
Total noncurrent liabilities:90,86996,93892,28090,90172,143122,791
Total liabilities:208,502224,100223,237201,258190,269185,840
Equity
Equity, attributable to parent710,134741,043805,743817,568739,072420,083
Common stock222222
Additional paid in capital2,177,6722,025,8901,839,3971,680,8651,544,218682,494
Accumulated other comprehensive income (loss)(493)(429)(4,335)22(50)(46)
Accumulated deficit(1,467,047)(1,284,420)(1,029,321)(863,321)(805,098)(262,367)
Total equity:710,134741,043805,743817,568739,072420,083
TOTAL LIABILITIES AND EQUITY:918,636965,1431,028,9801,018,826929,341605,923

Income Statement (P&L) ($ in thousands)

9/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues610,785618,727516,409490,490298,845245,893
Cost of revenue(196,303)(209,414)(120,386)(74,091)(58,468)(61,033)
Gross profit:414,482409,313396,023416,399240,377184,860
Operating expenses(609,041)(674,642)(563,967)(468,652)(774,519)(215,433)
Operating loss:(194,559)(265,329)(167,944)(52,253)(534,142)(30,573)
Nonoperating income (expense)16,85916,5665,973(1,462)(334)(460)
Investment income, nonoperating18,44816,9066,6472061,5322,805
Other nonoperating income (expense)(1,585)(307)(198)(802)1,337(186)
Interest and debt expense (4)(33)(476)(866)(1,521)(3,079)
Loss from continuing operations before equity method investments, income taxes:(177,704)(248,796)(162,447)(54,581)(535,997)(34,112)
Other undisclosed income from continuing operations before income taxes 4334768661,5213,079
Loss from continuing operations before income taxes:(177,700)(248,763)(161,971)(53,715)(534,476)(31,033)
Income tax expense(4,927)(6,336)(4,029)(4,508)(8,255)(218)
Loss from continuing operations:(182,627)(255,099)(166,000)(58,223)(542,731)(31,251)
Loss before gain (loss) on sale of properties:(58,223)(542,731)(31,251)
Net loss available to common stockholders, diluted:(182,627)(255,099)(166,000)(58,223)(542,731)(31,251)

Comprehensive Income ($ in thousands)

9/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(182,627)(255,099)(166,000)(58,223)(542,731)(31,251)
Comprehensive loss:(182,627)(255,099)(166,000)(58,223)(542,731)(31,251)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(64)3,906(4,357)72(4)(9)
Comprehensive loss, net of tax, attributable to parent:(182,691)(251,193)(170,357)(58,151)(542,735)(31,260)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: